Probiotics, immune function, infection and inflammation: a review of the evidence from studies conducted in humans

A number of studies have been performed examining the influence of various probiotic organisms, either alone or in combination, on immune parameters, infectious outcomes, and inflammatory conditions in humans. Some components of the immune response, including phagocytosis, natural killer cell activi...

Full description

Saved in:
Bibliographic Details
Published inCurrent pharmaceutical design Vol. 15; no. 13; p. 1428
Main Authors Lomax, A R, Calder, P C
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.05.2009
Subjects
Online AccessGet more information

Cover

Loading…
Abstract A number of studies have been performed examining the influence of various probiotic organisms, either alone or in combination, on immune parameters, infectious outcomes, and inflammatory conditions in humans. Some components of the immune response, including phagocytosis, natural killer cell activity and mucosal immunoglobulin A production (especially in children), can be improved by some probiotic bacteria. Other components, including lymphocyte proliferation, the production of cytokines and of antibodies other than immunoglobulin A appear less sensitive to probiotics. Probiotics, including lactobacilli and bifidobacteria, administered to children can reduce incidence and duration of diarrhoea, but the precise effects depend upon the nature of the condition. Probiotic supplementation can reduce the risk of travellers' diarrhoea in adults, but does not affect duration. The effect of probiotics on other infectious outcomes is less clear. Probiotics may benefit children and adults with irritable bowel syndrome and adults with ulcerative colitis; studies in Crohn's Disease are less clear. Probiotics have little effect in rheumatoid arthritis. Probiotic supplementation, especially with lactobacilli and bifidobacteria, can reduce risk and severity of allergic disease, particular atopic dermatitis; early supplementation appears to be effective. Overall, the picture that emerges from studies of probiotics on immune, infectious and inflammatory outcomes in humans is mixed and there appear to be large species and strain differences in effects seen. Other reasons for differences in effects seen will include dose of probiotic organism used, duration of supplementation, characteristics of the subjects studied, sample size, and technical differences in how the measurements were made.
AbstractList A number of studies have been performed examining the influence of various probiotic organisms, either alone or in combination, on immune parameters, infectious outcomes, and inflammatory conditions in humans. Some components of the immune response, including phagocytosis, natural killer cell activity and mucosal immunoglobulin A production (especially in children), can be improved by some probiotic bacteria. Other components, including lymphocyte proliferation, the production of cytokines and of antibodies other than immunoglobulin A appear less sensitive to probiotics. Probiotics, including lactobacilli and bifidobacteria, administered to children can reduce incidence and duration of diarrhoea, but the precise effects depend upon the nature of the condition. Probiotic supplementation can reduce the risk of travellers' diarrhoea in adults, but does not affect duration. The effect of probiotics on other infectious outcomes is less clear. Probiotics may benefit children and adults with irritable bowel syndrome and adults with ulcerative colitis; studies in Crohn's Disease are less clear. Probiotics have little effect in rheumatoid arthritis. Probiotic supplementation, especially with lactobacilli and bifidobacteria, can reduce risk and severity of allergic disease, particular atopic dermatitis; early supplementation appears to be effective. Overall, the picture that emerges from studies of probiotics on immune, infectious and inflammatory outcomes in humans is mixed and there appear to be large species and strain differences in effects seen. Other reasons for differences in effects seen will include dose of probiotic organism used, duration of supplementation, characteristics of the subjects studied, sample size, and technical differences in how the measurements were made.
Author Calder, P C
Lomax, A R
Author_xml – sequence: 1
  givenname: A R
  surname: Lomax
  fullname: Lomax, A R
  email: arl203@soton.ac.uk
  organization: Institute of Human Nutrition, School of Medicine, University of Southampton, Tremona Road, Southampton SO16 6YD, UK. arl203@soton.ac.uk
– sequence: 2
  givenname: P C
  surname: Calder
  fullname: Calder, P C
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19442167$$D View this record in MEDLINE/PubMed
BookMark eNo1j9tKxDAYhIMo7kFfwAvJA1jNnyZp6p2IJ1jQC71e0uQPG9kkS9Mqvr1dD1cz88EMzIIcppyQkDNglxwacQW1BgWctY2ejAYpD8gcdFNXgms1I4tS3hkD3oI4JjNoheCgmjnpX_rchTwEWy5oiHFMSP2Y7BBymkDy-GOpSW6ftiZGswfX1NAePwJ-0uzpsEE6BYfJTvU-R1qG0QUs1ObkRjvgvk03YzSpnJAjb7YFT_90Sd7u715vH6vV88PT7c2q6iQXQwVGMFaj1E4rNKisxrYFI623oH3tGoWOSSGZ6xrVoBEaGHTKG2C10NLwJTn_3d2NXUS33vUhmv5r_X-efwPb3l3t
CitedBy_id crossref_primary_10_3389_fmicb_2020_557143
crossref_primary_10_2147_DDDT_S363974
crossref_primary_10_3748_wjg_v25_i33_4999
crossref_primary_10_1111_j_1574_695X_2012_01014_x
crossref_primary_10_3389_fimmu_2021_643321
crossref_primary_10_1371_journal_pone_0068367
crossref_primary_10_1097_JD9_0000000000000152
crossref_primary_10_1080_17461391_2018_1449895
crossref_primary_10_3390_nu16081246
crossref_primary_10_1016_j_nutres_2018_12_011
crossref_primary_10_1128_msystems_00842_23
crossref_primary_10_1038_s41387_021_00165_0
crossref_primary_10_1155_2022_6234858
crossref_primary_10_2174_0127722708246899230928080651
crossref_primary_10_3920_BM2017_0139
crossref_primary_10_1111_1574_6968_12601
crossref_primary_10_3390_foods10092202
crossref_primary_10_22207_JPAM_15_3_21
crossref_primary_10_4236_fns_2014_518188
crossref_primary_10_1007_s00018_012_1028_z
crossref_primary_10_1080_20469047_2018_1535871
crossref_primary_10_1016_j_chemosphere_2022_135429
crossref_primary_10_1017_S0007114512004059
crossref_primary_10_3390_microorganisms8091265
crossref_primary_10_1111_j_1750_3841_2010_01875_x
crossref_primary_10_1136_bmjnph_2020_000085
crossref_primary_10_1016_j_lwt_2019_05_089
crossref_primary_10_4062_biomolther_2012_20_4_371
crossref_primary_10_3923_ijp_2017_361_369
crossref_primary_10_4049_jimmunol_1001751
crossref_primary_10_1016_j_carbpol_2018_06_042
crossref_primary_10_1016_j_foodres_2016_10_042
crossref_primary_10_2217_fmb_12_82
crossref_primary_10_1002_mnfr_201700171
crossref_primary_10_1017_S0007114512005119
crossref_primary_10_1016_j_exger_2009_08_011
crossref_primary_10_1186_s13102_022_00513_2
crossref_primary_10_1007_s00592_020_01563_z
crossref_primary_10_1017_S0029665123004792
crossref_primary_10_1017_S000711451100420X
crossref_primary_10_1073_pnas_1518189113
crossref_primary_10_3748_wjg_v22_i31_6972
crossref_primary_10_1186_s12906_015_0802_5
crossref_primary_10_1016_j_clnu_2017_01_011
crossref_primary_10_1080_10408398_2012_656772
crossref_primary_10_1007_s13213_012_0590_9
crossref_primary_10_1016_j_ajps_2017_01_003
crossref_primary_10_1371_journal_pone_0098942
crossref_primary_10_3390_fishes9070245
crossref_primary_10_1016_j_micpath_2018_12_048
crossref_primary_10_1007_s42770_023_01072_5
crossref_primary_10_1017_S0007114513004261
crossref_primary_10_1002_mnfr_201500665
crossref_primary_10_3920_BM2013_0079
crossref_primary_10_1016_j_copbio_2012_08_005
crossref_primary_10_1017_S0029665113001286
crossref_primary_10_3390_molecules26020472
crossref_primary_10_4161_gmic_2_5_18002
crossref_primary_10_1007_s12010_023_04827_w
crossref_primary_10_1038_s41430_021_00949_8
crossref_primary_10_53365_nrfhh_175070
crossref_primary_10_1007_s12325_022_02285_0
crossref_primary_10_3390_pathogens12070874
crossref_primary_10_4265_bio_26_75
crossref_primary_10_3389_fnut_2023_1075061
crossref_primary_10_1017_S0007114510005702
crossref_primary_10_1093_jn_nxaa353
crossref_primary_10_1016_j_rvsc_2017_03_008
crossref_primary_10_1007_s10787_012_0126_8
crossref_primary_10_1016_j_cofs_2021_12_006
crossref_primary_10_5124_jkma_2012_55_5_475
crossref_primary_10_1016_j_intimp_2015_04_021
crossref_primary_10_1080_14787210_2020_1782188
crossref_primary_10_1016_j_nut_2021_111419
crossref_primary_10_1017_S0954422416000263
crossref_primary_10_1007_s10787_017_0436_y
crossref_primary_10_1016_j_imbio_2010_01_004
crossref_primary_10_1007_s13668_020_00325_1
crossref_primary_10_1016_j_ejmech_2023_116075
crossref_primary_10_1007_s00394_012_0487_1
crossref_primary_10_1016_j_lwt_2016_08_009
crossref_primary_10_1002_vetr_4914
crossref_primary_10_1186_s12970_019_0290_y
crossref_primary_10_3310_eme08070
crossref_primary_10_3390_microorganisms8081141
crossref_primary_10_3390_nu12123636
crossref_primary_10_34172_bshj_36
crossref_primary_10_3920_BM2013_0014
crossref_primary_10_1097_MOG_0000000000000132
crossref_primary_10_1080_10408398_2011_645259
crossref_primary_10_1093_advances_nmac052
crossref_primary_10_1038_nrgastro_2014_66
crossref_primary_10_1111_j_1365_2125_2012_04404_x
crossref_primary_10_3945_ajcn_114_103531
crossref_primary_10_1371_journal_pone_0078420
crossref_primary_10_1111_ijfs_12239
crossref_primary_10_1186_1743_7075_10_49
crossref_primary_10_3920_BM2016_0147
crossref_primary_10_4161_gmic_1_6_13610
crossref_primary_10_1017_S0029665113003777
crossref_primary_10_1017_S175173111000193X
crossref_primary_10_5402_2011_584682
crossref_primary_10_1186_s13071_020_04073_7
crossref_primary_10_1128_AEM_06060_11
crossref_primary_10_1007_s10068_022_01069_0
crossref_primary_10_1080_10408398_2014_967385
crossref_primary_10_1179_joc_2010_22_6_373
crossref_primary_10_3892_etm_2017_4536
crossref_primary_10_1016_j_archoralbio_2017_04_026
crossref_primary_10_1016_j_jfoodeng_2010_12_031
crossref_primary_10_1093_ofid_ofab550
crossref_primary_10_1136_bmjopen_2018_027513
crossref_primary_10_1016_j_clnu_2013_02_004
crossref_primary_10_1111_j_1751_7915_2011_00329_x
crossref_primary_10_1017_S0007114524001405
crossref_primary_10_1123_ijsnem_2021_0335
crossref_primary_10_1089_jmf_2019_4467
crossref_primary_10_1111_1471_0307_12251
crossref_primary_10_3103_S1068367415050183
crossref_primary_10_1186_s12986_016_0154_2
crossref_primary_10_3389_fmicb_2022_1029890
crossref_primary_10_12944_CRNFSJ_9_3_04
crossref_primary_10_1016_j_idairyj_2010_03_005
crossref_primary_10_1017_S0007114520003980
crossref_primary_10_1007_s00394_015_1109_5
crossref_primary_10_2139_ssrn_3745788
crossref_primary_10_1017_S0007114513001505
crossref_primary_10_1056_NEJMoa1802598
crossref_primary_10_3746_jfn_2009_14_3_265
crossref_primary_10_1007_s12602_018_9396_9
crossref_primary_10_3389_fimmu_2017_01443
crossref_primary_10_3390_ijerph16173128
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.2174/138161209788168155
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-4286
ExternalDocumentID 19442167
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GroupedDBID ---
.5.
0R~
29F
36B
3V.
4.4
53G
5GY
69Q
7X7
88E
8AO
8FI
8FJ
8R4
8R5
AAEGP
ABEEF
ABJNI
ABUWG
ABVDF
ACGFO
ACGFS
ACITR
ACIWK
ACPRK
ACZAY
ADBBV
AENEX
AFKRA
AFRAH
AFUQM
AGJNZ
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ANTIV
BENPR
BPHCQ
BVXVI
C1A
CCPQU
CGR
CS3
CUY
CVF
DU5
EBS
ECM
EIF
EJD
F5P
FYUFA
GH2
HMCUK
HZ~
IPNFZ
KCGFV
KFI
M1P
NPM
O9-
P2P
PQQKQ
PROAC
PSQYO
Q2X
RIG
UKHRP
ID FETCH-LOGICAL-b524t-1a4003e58d86eae6c8e991a5cfc18f3d76ed05450db767ea48101b6fa103485a2
IngestDate Thu Jan 02 23:00:56 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 13
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-b524t-1a4003e58d86eae6c8e991a5cfc18f3d76ed05450db767ea48101b6fa103485a2
PMID 19442167
ParticipantIDs pubmed_primary_19442167
PublicationCentury 2000
PublicationDate 2009-05-01
PublicationDateYYYYMMDD 2009-05-01
PublicationDate_xml – month: 05
  year: 2009
  text: 2009-05-01
  day: 01
PublicationDecade 2000
PublicationPlace United Arab Emirates
PublicationPlace_xml – name: United Arab Emirates
PublicationTitle Current pharmaceutical design
PublicationTitleAlternate Curr Pharm Des
PublicationYear 2009
SSID ssj0012914
Score 2.372362
SecondaryResourceType review_article
Snippet A number of studies have been performed examining the influence of various probiotic organisms, either alone or in combination, on immune parameters,...
SourceID pubmed
SourceType Index Database
StartPage 1428
SubjectTerms Adult
Child
Clinical Trials as Topic
Gastrointestinal Diseases - immunology
Gastrointestinal Diseases - therapy
Humans
Immune System - drug effects
Immune System - metabolism
Infection - immunology
Infection - therapy
Inflammation - drug therapy
Inflammation - immunology
Probiotics - pharmacology
Probiotics - therapeutic use
Title Probiotics, immune function, infection and inflammation: a review of the evidence from studies conducted in humans
URI https://www.ncbi.nlm.nih.gov/pubmed/19442167
Volume 15
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELUoXLggKF-lpZoD6oVN2SS243BDFVWFAO1hK_VWTWJHILEfYvdA-fXMZJxNthRUuESRrURR3svEM555o9SrosQ05LpIkD4HclAaTCq0LvGZzbgjHC3peUf302d7dq4_XJiLPnWorS5ZV8f1zxvrSv4HVRojXLlK9h-Q3dyUBuic8KUjIUzHW2E8aUWU1jHX5yuXeoTX_KdqMzZ4KKZazaPIUkP4zzb5HDgoXGlzO2KHUak5WUmGIeelsyZs4Oulpd9quKLtBJ6WX7aC434rM-TjYoY_xAxtdpZO8JsXvkxiqLYLPpR9qt9xEIPpijwhF8ZuWVQzZE4-sI-s73aT4WbHiGMIvI3J1bwscm9dKgq-AySXsxbKtNQ6S6WPx99nr4lpd1M7aofcCu6TysGduOmUlamWuip-nDe_P0yrMCs3uOaFtKuR6UP1ILoR8E448UjdCfNddTQRDK5GMO3L6lYjOIJJr1B-9Vh974kzAqENdLShgY40QKSBIWneAoJQBhYNEGWgowwwZSBSBjaUoatBKPNEnZ--n56cJbH5RlKZTK-TFMm658E472zAYGsXyJVAUzd16prcFzZ4Wu6bsa8KWwTUrBRX2QbTca6dweypujtfzMNzBT7zBr0tK2614IJGLBpdh7HBWvuiHu-pZ_IuL5eisHLZveUXf5zZV_d7Ph6oew190uElrQ_X1WGL6i-AHWXY
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Probiotics%2C+immune+function%2C+infection+and+inflammation%3A+a+review+of+the+evidence+from+studies+conducted+in+humans&rft.jtitle=Current+pharmaceutical+design&rft.au=Lomax%2C+A+R&rft.au=Calder%2C+P+C&rft.date=2009-05-01&rft.eissn=1873-4286&rft.volume=15&rft.issue=13&rft.spage=1428&rft_id=info:doi/10.2174%2F138161209788168155&rft_id=info%3Apmid%2F19442167&rft_id=info%3Apmid%2F19442167&rft.externalDocID=19442167